On the recordMay 22, 2023
Is bad enough that they have such monopolistic or oligopolistic control that they influence prices.
Source
congress.govIs bad enough that they have such monopolistic or oligopolistic control that they influence prices.
Highlighting the negative impact of PBMs on drug pricing.
Share & report
More from Jimmy Gomez
Nobody, after receiving a cancer diagnosis, should then face the indignity of learning that our health system can't even provide the basic generic drugs to help them fight their disease.
I appreciate the bipartisan attention that this issue is receiving, that this hearing is attracting, and look forward to finding solutions for all of our constituents.
Madam Speaker, during Immigrant Heritage Month, I rise to honor my constituent Maria Barahona, a shining example of the resilience and contributions of our immigrant community. Maria, a home-care provider and TPS recipient from El…